Alaunos Therapeutics (NASDAQ:TCRT) Posts Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) released its quarterly earnings results on Friday. The company reported ($0.59) EPS for the quarter, FiscalAI reports.

Alaunos Therapeutics Price Performance

Shares of TCRT traded down $0.05 during mid-day trading on Friday, hitting $2.47. The company’s stock had a trading volume of 8,468 shares, compared to its average volume of 10,772. The firm has a 50-day moving average price of $2.93 and a 200 day moving average price of $3.05. The stock has a market capitalization of $5.93 million, a price-to-earnings ratio of -1.12 and a beta of -1.13. Alaunos Therapeutics has a fifty-two week low of $1.67 and a fifty-two week high of $6.20.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics at the end of the most recent reporting period. Institutional investors own 27.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Alaunos Therapeutics currently has an average rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.